rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Aclaris Therapeutics, Inc.

ACRS · Nasdaq

Health CareBiotechnologyNot moving yet

ACRS stood above a rising 150-day average in 49 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 32.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$2.7M
Officials’ trades on record
0
Institutions holding
143 (+16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 49 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.6M$0$1.3MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Braden Michael Leonard10% ownersold300,000at $4.5323 Apr 2026filed 27 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders143+16 on the quarter
New · exited30 · 15
Reported value$619.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RA CAPITAL MANAGEMENT, L.P.added · filed 14 Aug 202612,723,026$67.3M+5,918,954+87.0%
BML Capital Management, LLCreduced · filed 7 Aug 202611,975,000$63.3M-2,275,000−16.0%
BlackRock, Inc.added · filed 7 Aug 202610,037,008$53.1M+2,629,943+35.5%
Deep Track Capital, LPunchanged · filed 14 Aug 20269,345,000$49.4M00.0%
Vivo Capital, LLCadded · filed 14 Aug 20266,694,637$35.4M+27,971+0.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20265,817,866$30.8M+650,397+12.6%
Frazier Life Sciences Management, L.P.unchanged · filed 14 Aug 20264,925,374$26.1M00.0%
Rock Springs Capital Management LPreduced · filed 14 Aug 20264,330,532$22.9M-142,118−3.2%
ADAGE CAPITAL PARTNERS GP, L.L.C.added · filed 14 Aug 20264,071,000$21.5M+200,000+5.2%
Decheng Capital LLCunchanged · filed 14 Aug 20264,041,736$21.4M00.0%
31 Mar 2023 – 30 Jun 2026
72106140Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Roland Wilhelm Kolbeck Company insiderChief Scientific Officer · last 1 Aug 20260 · 0
Anand Mehra Company insiderDirector · last 5 Jun 20263 · 1
Andrew N. Schiff Company insiderDirector · last 5 Jun 20261 · 12
Christopher P. Molineaux Company insiderDirector · last 5 Jun 20260 · 1
Maxine Gowen Company insiderDirector · last 5 Jun 20260 · 0
Vincent Milano Company insiderDirector · last 5 Jun 20260 · 0
William D. Humphries Company insiderDirector · last 5 Jun 20260 · 0
Jesse Wayne Hall Company insiderChief Medical Officer · last 1 May 20260 · 0
Braden Michael Leonard Company insider10% owner · last 23 Apr 202619 · 1
Kevin Balthaser Company insiderChief Financial Officer · last 1 Mar 20261 · 2
Hugh M. Davis Company insiderPresident and COO · last 3 Feb 20260 · 0
James Loerop Company insiderChief Business Officer · last 3 Feb 20261 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202573.3%
Operating profit marginFY 2025 · to 31 Dec 2025-976%
Free cash flow marginFY 2025 · to 31 Dec 2025-603%
Return on capital employedFY 2025 · to 31 Dec 2025-57.9%
Research spendFY 2024 · to 31 Dec 2024179%
Share count trendFY 2025 · to 30 Jan 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$20.0M
Free cash flowFY 2025 · to 31 Dec 2025−$47.2M

Analyst forecasts

No analyst forecasts yet.